A021901 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Study Number: A021901 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Please Note:

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.

Available Sites

• Missouri Baptist Medical Center

Contact Person(s)

• Patricia Kulla, 314-996-4617

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.